Profound Medical (PROF): The Q2 Number That Fooled the Headline and the Cash Math That Actually Matters

Not a great quarter in the stock market for Profound Medical, even though the company is executing what is arguably the most compelling compounding story in the small-cap meddevice space. The stock slipped 3.5% after the report. Most headlines fixated on revenue of CAD 2.5 million, up 12% year over year, and filed it under "slow growth." They missed the mechanism.

About $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing. Revenue shifted to July and gets recognized in Q3. Without that logistics hiccup, Q2 revenue would have been roughly $5.6 million — 153% year-over-year growth. The demand plumbing is fine. The delivery pipe had a kink.

Once you set aside the timing noise, the real story is in the numbers nobody leads with. Gross margin expanded to 78%, up from 73% a year ago, driven by a better product mix that includes more capital system sales and fewer operating leases (where the company carries the depreciation). Net loss shrank 39%, from $15.7 million to $9.5 million, because operating expenses dropped 16% as the CAPTAIN clinical trial enrollment wrapped and personnel and clinical costs came off the table. Management is targeting full-year gross margins above 70% — they're already doing it, just averaging in lower-margin quarters from the first half.

Here's the plumbing check that actually matters for a pre-profitability company: Profound ended Q2 with $38.3 million in cash and 36.5 million shares outstanding. At a net loss of roughly $9.5 million per quarter — and that number should continue to decline as revenue grows past the fixed-cost base — the company has about four quarters of runway at the current burn rate. Four quarters is not an emergency, but it's not comfortable either. If the $70 million qualified pipeline doesn't convert into revenue at a pace that narrows the gap between top-line growth and cash consumption, dilution becomes the headline, not clinical data or Medicare reimbursement. Understanding what I understand about spreads and economics would tell me that a pre-profit company with four quarters of cash is trading in the zone where execution risk dominates narrative upside.

But the pipeline number is not a fantasy figure. It sits at roughly $70 million in the verify, negotiate, and contracting stages — 90% TULSA-PRO, 10% Sonalleve, their second product for benign prostatic hyperplasia. The install base grew to 84 systems by the end of Q2, up from 78 at year-end 2025. New purchase orders hit a quarterly record of over $7 million in Q2 alone. Management cited record order activity in July and 160-plus qualified opportunities from the Society of Robotic Surgery conference. The qualified pipeline-to-install-base ratio is telling: each of the 84 existing systems should be generating meaningful recurring revenue, and the $70 million in pipeline implies roughly 40-50 additional systems if the average deal is in the $1.5-$1.8 million range. That would push the install base toward 125-135 by year-end, well past the target they exceeded last January.

The thing that makes Profound different from most meddevice startups is the recurring revenue model layered on top of the equipment sale. In the U.S., they deploy a hybrid recurring revenue business model: a one-time capital payment that includes an initial supply of disposable transducers, then recurring per-procedure revenue from consumable refills. The consumables have high margins — part of what drives that 78% gross margin. Once a system is installed and a urologist is trained, the customer is locked into buying their transducers. The more procedures the site runs, the more recurring revenue Profound earns. It's the classic razor-and-blades model, which is why the utilization metric matters so much.

Here's where I pause. The INDEX 20 — their cohort measure of average procedures per quarter at 20 active sites — came in at 10.0 procedures, down 12% sequentially from 11.3 in Q1. Management attributed the dip to five underperforming sites, including a high-value location pausing treatments during a transition from placement to capital ownership. Year-over-year, INDEX 20 is still up 22%, and the first half saw 39% growth. One quarter of sequential weakness doesn't break the trend line, but it does remind you that utilization is a behavioral metric, not a mechanical one. Urologists have to actually choose TULSA over their existing procedures, quarter after quarter. Half of Q2 ablations were whole-gland (malignant tissue, 71% of the mix), which is the high-value treatment profile that justifies the equipment investment. The utilization trend is worth watching in Q3.

Now the reimbursement angle, because this is where the competitive moat is. Under proposed 2027 Medicare rules, TULSA sits at urology APC level 7 with a proposed payment increase of 14.9% to $15,494 per procedure. HIFU — the closest competing focal therapy — gets $10,797. That's a 44% premium for TULSA. Robotic radical prostatectomy, the current gold-standard surgery, gets $12,300. On the physician payment schedule, the gap narrows, but the hospital facility payment still favors TULSA. Add on private payer expansion: coverage grew by roughly 18.3 million lives in Q2 alone, pushing the first-half total to about 30 million newly covered lives outside Medicare. Johns Hopkins and Prime Healthcare both added TULSA coverage this quarter. Reimbursement isn't just about getting paid — it's about getting paid more than the alternative, which creates a built-in incentive for hospitals to adopt the technology.

The clinical evidence backs this up. The CAPTAIN Level 1 randomized trial — the highest evidence level for comparing treatments — showed TULSA with statistically superior quality-of-life outcomes versus robotic radical prostatectomy: better urinary continence, better erectile function, fewer serious complications, faster recovery. At one month, TULSA showed zero median penile-length reduction versus a 0.65-centimeter reduction with robotic surgery. The histology and imaging results for the TULSA arm are expected in Q4, which is the next data catalyst. If those margins look clean, you have Level 1 evidence supporting both oncologic safety and quality-of-life superiority. That's the kind of data that moves adoption curves.

So here's the framing. Yes, you could argue that $38 million in cash against a $9.5 million quarterly burn is tight and that dilution is the default path for a company this small. That's fair. But the pipeline is real, the reimbursement premium is structural, the clinical data is at the highest evidence level, and the recurring revenue model starts compounding as the install base crosses 100 systems. The question isn't whether the technology works — CAPTAIN answered that. The question is whether the sales cycle is short enough to convert $70 million in pipeline before cash gets uncomfortable.

The conditional chain I'm watching: if Q3 and Q4 see pipeline conversion at a rate that pushes annualized recurring revenue past $10 million, the burn rate starts looking manageable and the dilution overhang fades. If shipments slow or utilization dips again, cash gets to the $25 million range and the narrative shifts from "growth story" to "capital raise." The TOLMENT histology data in Q4 is the secondary catalyst — clean margins reinforce the clinical case and accelerate adoption.

Same technology. Same reimbursement advantage. Different execution quarter every time, which is the whole point of this trade. Watch the Q3 revenue number, the INDEX 20 utilization trend, and the cash balance. The mechanism tells you when to add or trim — not the narrative.

The views expressed here are personal analysis, not investment advice. Profound Medical is a speculative, pre-profitability medical device company. Investors should consider the risks of dilution, execution, and competitive dynamics before allocating capital.